Literature DB >> 23869564

Biological and structural evaluation of 10R- and 10S-methylthio-DDACTHF reveals a new role for sulfur in inhibition of glycinamide ribonucleotide transformylase.

Stephen Connelly1, Jessica K DeMartino, Dale L Boger, Ian A Wilson.   

Abstract

Glycinamide ribonucleotide transformylase (GAR Tfase) is a folate-dependent enzyme in the de novo purine biosynthesis pathway, which has long been considered a potential target for development of anti-neoplastic therapeutics. Here we report the biological and X-ray crystallographic evaluations of both independent C10 diastereomers, 10S- and 10R-methylthio-DDACTHF, bound to human GAR Tfase, including the highest-resolution apo GAR Tfase structure to date (1.52 Å). Both diastereomers are potent inhibitors (Ki = 210 nM for 10R, and Ki = 180 nM for 10S) of GAR Tfase and exhibit effective inhibition of human leukemia cell growth (IC₅₀ = 80 and 50 nM, respectively). Their inhibitory activity was surprisingly high, and these lipophilic C10-substituted analogues show distinct advantages over their hydrophilic counterparts, most strikingly in retaining potency in mutant human leukemia cell lines that lack reduced folate carrier protein activity (IC₅₀ = 70 and 60 nM, respectively). Structural characterization reveals a new binding mode for these diastereoisomers, in which the lipophilic thiomethyl groups penetrate deeper into a hydrophobic pocket within the folate-binding site. In silico docking simulations of three other sulfur-containing folate analogues also indicate that this hydrophobic cleft represents a favorable region for binding lipophilic substituents. Overall, these results suggest sulfur and its substitutions play an important role in not only the binding of anti-folates to GAR Tfase but also the selectivity and cellular activity (growth inhibition), thereby presenting new possibilities for the future design of potent and selective anti-folate drugs that target GAR Tfase.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23869564      PMCID: PMC3823235          DOI: 10.1021/bi4005182

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  77 in total

1.  PRODRG: a tool for high-throughput crystallography of protein-ligand complexes.

Authors:  Alexander W Schüttelkopf; Daan M F van Aalten
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2004-07-21

2.  WHAT IF: a molecular modeling and drug design program.

Authors:  G Vriend
Journal:  J Mol Graph       Date:  1990-03

Review 3.  Roles of folylpoly-gamma-glutamate synthetase in therapeutics with tetrahydrofolate antimetabolites: an overview.

Authors:  R G Moran
Journal:  Semin Oncol       Date:  1999-04       Impact factor: 4.929

4.  Structures of NADH and CH3-H4folate complexes of Escherichia coli methylenetetrahydrofolate reductase reveal a spartan strategy for a ping-pong reaction.

Authors:  Robert Pejchal; Ryan Sargeant; Martha L Ludwig
Journal:  Biochemistry       Date:  2005-08-30       Impact factor: 3.162

5.  Virtual screening of human 5-aminoimidazole-4-carboxamide ribonucleotide transformylase against the NCI diversity set by use of AutoDock to identify novel nonfolate inhibitors.

Authors:  Chenglong Li; Lan Xu; Dennis W Wolan; Ian A Wilson; Arthur J Olson
Journal:  J Med Chem       Date:  2004-12-30       Impact factor: 7.446

6.  Multisubstrate analogue based on 5,8,10-trideazafolate.

Authors:  D L Boger; N E Haynes; M S Warren; J Ramcharan; P A Kitos; S J Benkovic
Journal:  Bioorg Med Chem       Date:  1997-09       Impact factor: 3.641

7.  Crystal structures of recombinant human dihydrofolate reductase complexed with folate and 5-deazafolate.

Authors:  J F Davies; T J Delcamp; N J Prendergast; V A Ashford; J H Freisheim; J Kraut
Journal:  Biochemistry       Date:  1990-10-09       Impact factor: 3.162

8.  Weekly lometrexol with daily oral folic acid is appropriate for phase II evaluation.

Authors:  J D Roberts; E A Poplin; M B Tombes; B Kyle; D V Spicer; S Grant; T Synold; R Moran
Journal:  Cancer Chemother Pharmacol       Date:  2000       Impact factor: 3.333

9.  Design, synthesis, and biological evaluation of simplified alpha-keto heterocycle, trifluoromethyl ketone, and formyl substituted folate analogues as potential inhibitors of GAR transformylase and AICAR transformylase.

Authors:  Thomas H Marsilje; Michael P Hedrick; Joel Desharnais; Ali Tavassoli; Yan Zhang; Ian A Wilson; Stephen J Benkovic; Dale L Boger
Journal:  Bioorg Med Chem       Date:  2003-10-01       Impact factor: 3.641

10.  N10-Formyltetrahydrofolate is the formyl donor for glycinamide ribotide transformylase in Escherichia coli.

Authors:  I K Dev; R J Harvey
Journal:  J Biol Chem       Date:  1978-06-25       Impact factor: 5.157

View more
  4 in total

1.  Pathway genes and metabolites in thiopurine therapy in Korean children with acute lymphoblastic leukaemia.

Authors:  Rihwa Choi; Insuk Sohn; Min-Ji Kim; Hye In Woo; Ji Won Lee; Youngeun Ma; Eun Sang Yi; Hong Hoe Koo; Soo-Youn Lee
Journal:  Br J Clin Pharmacol       Date:  2019-05-27       Impact factor: 4.335

2.  Network correlation analysis revealed potential new mechanisms for neural tube defects beyond folic acid.

Authors:  Xiaoya Gao; Richard H Finnell; Hongyan Wang; Yufang Zheng
Journal:  Birth Defects Res       Date:  2018-05-06       Impact factor: 2.344

3.  Novel 5-substituted pyrrolo[2,3-d]pyrimidines as dual inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase and as potential antitumor agents.

Authors:  Yiqiang Wang; Shermaine Mitchell-Ryan; Sudhir Raghavan; Christina George; Steven Orr; Zhanjun Hou; Larry H Matherly; Aleem Gangjee
Journal:  J Med Chem       Date:  2015-02-02       Impact factor: 7.446

4.  In silico analysis of glycinamide ribonucleotide transformylase inhibition by PY873, PY899 and DIA.

Authors:  Sidra Batool; Muhammad Sulaman Nawaz; Gohar Mushtaq; Fahed Parvaiz; Mohammad A Kamal
Journal:  Saudi J Biol Sci       Date:  2014-11-22       Impact factor: 4.219

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.